期刊
DISEASE MODELS & MECHANISMS
卷 15, 期 2, 页码 -出版社
COMPANY BIOLOGISTS LTD
DOI: 10.1242/dmm.048953
关键词
Drosophila; Mouse xenografts; Leukemia; Oncogenic RAS; Echinomycin; Hypoxia pathway; HIF1A
资金
- National Institute of Diabetes and Digestive and Kidney Diseases [R01-DK098410]
- National Heart, Lung, and Blood Institute [R01-HL134940]
- National Institute of Allergy and Infectious Diseases [R01-AI064350]
This study investigates the role of oncogenic Ras proteins in acute myeloid leukemia using a Drosophila model. Through genetic and drug screens, the researchers identify candidate genes and a potential targeted drug, echinomycin, that can attenuate oncogenic Ras-induced cancer phenotypes. The study suggests that inhibiting the hypoxia pathway could be an effective treatment approach.
Oncogenic Ras mutations are highly prevalent in hematopoietic malignancies. However, it is difficult to directly target oncogenic RAS proteins for therapeutic intervention. We have developed a Drosophila acute myeloid leukemia model induced by human KRAS(G12V), which exhibits a dramatic increase in myeloid-like leukemia cells. We performed both genetic and drug screens using this model. The genetic screen identified 24 candidate genes able to attenuate the oncogenic RAS-induced phenotype, including two key hypoxia pathway genes HIF1A and ARNT (HIF1B). The drug screen revealed that echinomycin, an inhibitor of HIF1A, can effectively attenuate the leukemia phenotype caused by KRAS(G12V). Furthermore, we showed that echinomycin treatment can effectively suppress oncogenic RAS-driven leukemia cell proliferation, using both human leukemia cell lines and a mouse xenograft model. These data suggest that inhibiting the hypoxia pathway could be an effective treatment approach and that echinomycin is a promising targeted drug to attenuate oncogenic RAS-induced cancer phenotypes. This article has an associated First Person interview with the first author of the paper.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据